Nevertheless, our findings showed that CGA treatment activated PPARγ to a degree similar to RG treatment, potentially explaining the ability of CGA to increase insulin sensitivity and inhibit chronic inflammation caused by obesity [17, 21, 22, 25]. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.